Autopsy report · NCT01053221

Mycophenolic Acid Monotherapy in Recipients of HLA-identical Living-Related Transplantation

“Funding loss”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 years 10 months after it had already started.
• Ran for about 6 years 5 months before it stopped.
• 16 participants enrolled.
• Results were posted on the registry 6 years 11 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

University of Wisconsin, Madison

Sponsor type

University, hospital or other

Conditions

Kidney Transplantation

Interventions

Mycophenolic Acid; Standard of Care: CNI and MPA

Participants

16

Sites

1

Countries

United States

Trials that died the same way

• A Phase II Neoadjuvant Study of Enzalutamide, Abiraterone Acetate, Dutasteride and Degarelix in Men With Localized Prostate Cancer Pre-prostatectomy
  “loss of funding” (97% match in meaning)
• Meru Health Program to Treat Depression in Primary Care
  “Loss of grant funding.” (86% match in meaning)
• Mepolizumab for Eosinophilic Fasciitis
  “Funding lost from Sponsor.” (86% match in meaning)
• The Addition of Metformin to Definitive Radiotherapy in Patients With Stage III NSCLC
  “Loss of external funding” (85% match in meaning)
• A Randomized Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Effects of Alagebrium on Exercise in Subjects With Diastolic Heart Failure
  “Sponsor lost funding” (81% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.